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NMO in pediatric patients
Brain involvement and clinical expression
Joaquín A. Peña1, María Elena Ravelo2,
Eduardo Mora-La Cruz3, Cecilia Montiel-Nava4
ABSTRACT
Objective: To analyze the clinical, neuroimaging characteristics and positivity of the 
acquaporin water channel (NMO-IgG) in pediatric patients with neuromyelitis optica (NMO). 
This disorder could have a variable clinical expression. To address such variability, the 
term NMO spectrum has been suggested. Method: We evaluated six pediatric patients, 
with a median age of 11 years at the time of the study, with the diagnosis of NMO by 
the Wingerchuck criteria. Results: All the cases exhibited bilateral optic neuritis (ON). 
Four patients had abnormalities on brain MRI from the onset,although only three of them 
developed symptoms correlated to those lesions during the course of their disorder. NMO-
IgG was positive in 80%. Conclusion: Optic neuropathy is the most impaired feature in 
NMO patients. Brain MRI lesions are not compatible with multiple sclerosis and positivity 
of the NMO-IgG are also present in NMO pediatric patients, confirming the heterogeneity 
in the expression of this disorder. 
Key words: neuromyelitis optica, multiple sclerosis, optic neuritis, transverse myelitis, 
pediatric patients.
NMO en pacientes pediátricos: afectación del cerebro y expresión clínica
RESUMEN
Objetivo: Analizar las características clínicas y de neuroimagen, y la positividad del canal de 
agua acuaporin (NMO-IgG) en pacientes pediátricos con neuromielitis óptica (NMO). Este 
trastorno puede tener una expresión clínica variable. El término espectro de NMO ha sido 
propuesto para poder incluir la variabilidad. Metodo: Evaluamos seis pacientes pediátricos, 
con una mediana de edad de 11 años al momento del estudio, con el diagnóstico de 
NMO de acuerdo a los criterios de Wingerchuck. Resultados: Todos los casos exhibían 
neuritis óptica bilateral (ON). Cuatro pacientes tuvieron anormalidades en la RM cerebral 
desde el inicio, aunque solo tres de ellos desarrollaron síntomas relacionados con las 
lesiones durante el curso de la enfermedad. NMO-IgG fue positiva en el 80%. Conclusión: 
Neuropatía óptica es la característica mayormente observada en los pacientes con NMO. 
Lesiones cerebrales en la RM cerebral no compatibles con esclerosis multiple y positividad 
de la NMO-IgG están también presentes en los pacientes pediátricos con NMO; lo cual 
confirma la heterogeneidad en la expresión clínica de este trastorno. 
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Neuromyelitis optica (NMO) is an un-
common inflammatory demyelinating 
disorder characterized by severe acute 
transverse myelitis (TM) with bilateral 
simultaneous or sequential optic neuri-
tis (ON). Usually reported in adults and 
rarely in children, NMO has been consid-
ered an exceptional manifestation of mul-
tiple sclerosis (MS)1-5. However, it seems to 





ing pathogenesis, and more severe course6,7. This disor-
der could have a variable clinical expression which makes 
difficult its identification during its initial stages. To ad-
dress such variability the term of neuromyelitis optica 
spectrum has been suggested6, 8.
The 1999 diagnostic criteria for NMO required ful-
fillment of three absolute criteria: optic neuritis, acute 
myelitis, and no symptoms and/or MRI findings beyond 
the optic nerves and spinal cord9. The Pediatric Multi-
ple Sclerosis Study Group adopted the modified criteria 
from 200510 excluding patients with brain lesions; how-
ever, the Study Group acknowledged that these criteria11 
were also applicable to the pediatric patients8,10. In 2006, 
a new revised diagnostic criteria for definite NMO were 
defined due to the description of a sensitive and specific 
serum antibody which was called NMO immunoglobu-
lin G (NMO-IgG)12,13. These criteria included the occur-
rence of optic neuritis and transverse myelitis and at least 
two of three supportive criteria: MRI demonstrating in-
volvement of a three or more contiguous spinal cord seg-
ments, brain MRI with lesions not compatible with mul-
tiple sclerosis or NMO-IgG seropositivity11.
The introduction of the new criteria brought some 
difficulties to the NMO pediatric group (also to the adult 
group) due to the acceptance of white matter lesions seen 
in brain MRI11. 
Although spinal cord lesions are considered the land-
mark of NMO in children, it has been suggested that 
around half of the children with the diagnosis of NMO 
have neuroimaging evidence of brain lesions as well14-16. 
Furthermore, several lesions located in the hypothalamus, 
brainstem or diffuse cerebral white matter have been de-
scribed in children with typical features of NMO14,16. 
Another controversial diagnostic issue is related to the 
role of the serologic findings in pediatric NMO concern-
ing the specific serum antibody NMO-IgG. The aquapo-
rin 4-specific (AQP4) water channel autoantibody NMO-
IgG is detected in 73% of adults with NMO. However, 
Banwell, Tenembaun, and cols.16 reported that NMO-IgG 
in pediatric patients is a sensitive marker only for relaps-
ing NMO.
The reports of NMO in children are limited and more 
complexity is added to the disease characterization. Ten 
years ago, in 1999, the diagnostic criteria for NMO were 
first described and ever since two other criteria have been 
developed. These changes, linked to the low prevalence of 
the disorder in pediatric ages, have made more difficult 
the study of the true nature of NMO in children. Due to 
the dearth of information regarding pediatric NMO we 
aim to describe the clinical presentation as well as the 
neuroimaging characterization and the presence of the 
NMO immunoglobulin G antibody in a cohort of pedi-
atric patients with NMO.
METHOD
The patients described in this study were chil-
dren seen in two different cities in Venezuela: [1] the 
Neuropediatrics Service of the JM de los Rios Pediatric 
Hospital, in Caracas, and [2] The University Hospital in 
Maracaibo. Maracaibo and Caracas are the most popu-
lated cities in the country. All patients in Maracaibo were 
examined by the principal author (Dr. Peña), and those 
in Caracas by the second author (Dr. Ravelo). The chil-
dren were first seen between December 2002 and De-
cember 2008. The diagnosis of inflammatory demyelin-
ation encompassing the spectrum of neuromyelitis optica 
was based on clinical symptomatology, MRI and serolog-
ic analysis, which are in compliance with the most recent 
pediatric NMO diagnostic criteria11, which states that for 
a NMO diagnosis a child needs: optic neuritis and trans-
verse myelitis and at least two of three supportive crite-
ria (MRI demonstrating involvement of a three or more 
contiguous spinal cord segments, brain MRI with lesions 
not compatible with multiple sclerosis or NMO-IgG an-
tibody seropositivity). Patients’ information concerning 
age, symptoms in each bout, number of bouts, labora-
tory findings, MRI results and treatment were reviewed 
for each patient. 
The brain and spine MRI scans of each patient were 
reviewed by radiologists who were blind to the diagno-
sis within the MS spectrum. Most of the scans were per-
formed within two months from the onset of the symp-
toms and the criteria for the revision were: number, lo-
cation, size, and enhancement characteristics of the le-
sions. For the spinal cord scans the spinal segment length 
was also recorded.
Serum samples from all but one child were analyzed 
for NMO-IgG antibody in the Mayo Clinic Neuroimmu-
nology Laboratory. For each child, oligoclonal IgG bands 
in cerebrospinal fluid were tested in the Neuroimmunol-
ogy Laboratory of the Universidad Central de Venezue-
la. This study was usually requested after the first MRI 
scan was performed. Parents and guardians filled out an 
Informed Consent.
Six patients, five females and one male, were evaluat-
ed. Age at symptoms onset ranged from five to 13 years 
and the median age at the time of the study was 11 years 
old. They all presented three or more different bouts of a 
demyelinating disorder with brain and/or vertebral MRI 
confirmation. Five patients were white / non-Caucasian, 
and one was Amerindian. All children were of Venezu-
elan origin, with no family history of any demyelinating 
disorder. 
RESULTS
Patients’ characteristics, clinical, laboratory and MRI 






In three patients ON was the initial presentation fol-
lowed by TM (patients 1, 2 and 5), being apart for seven, 
five and eight months respectively. On the contrary, ON 
followed the initial presentation of TM six months lat-
er in patient 4, and ON occurred concurrently with TM 
in patients 3 and 6. All the cases exhibited bilateral ON 
with severe impairment in five of them. At the last med-
ical examination, all patients showed evidence of bilater-
al vision loss and crural paraparesis. Patients 1, 2, 5 and 6 
had complete vision loss in both eyes, and the other two 
children had partial vision recovery in both eyes.
Table. Clinical and demographic characteristics of the sample.
Case 1 2 3 4 5 6
Age 12 13 13 12 8 8
Gender Female Female Female Male Female Female













1st and 2nd attacks
7 months 5 months 2 months 6 months 8 months 2 months
Current treatment AZT AZT, Prednisone Prednisone, AZT Prednisone AZT, Prednisone AZT, Prednisone
MRI/spine C2-C5, C7-T4 C6-D8, D10-D11 C2-C6, D1-D3 C1-T5 C6-D8, D10-D11 C2-C5, D1-D10
Brain PV PV, CR PV, CR, CC PV, CR, 
Cerebellum
No. of attacks 5 7 3 3 4 3












NMO-IgG (y) Pos (19) Pos (15.2) Pending Neg (13) Pos (12.5) Pos (11)
AZT: azathioprine; PV: periventricular; CR: corona radiate; CC: corpus callosum; ON: optic neuritis.
Fig 1. MRI scans of the spinal cord in patients 2 [A] and 5 [B, C] with 
NMO. [A] Longitudinally extensive irregular lesion from T4 to T9 
levels. [B] Swollen cervical spinal cord with a longitudinally exten-
sive lesion involving the central area of the cord. [C] Axial imaging 
of cervical cord showing central pattern of involvement. Fig 2. Abnormal brain MRI in patients with NMO. [A] Patient 1: axial 
T1-weighted images showing several hyperintense lesions in peri-
ventricular area. [B] Patient 5: axial T1-weighted images displaying 
white matter hyperintense lesions; the saggital images show le-
sions in corpus callosum and pons. [C] Patient 6: axial T1-weight-
ed images of hyperintense lesions in thalamus, corpus callosum, 






As mentioned before, only in one patient the TM 
was the initial presentation (patient 4); however, clini-
cal symptoms related to TM were seen in all cases dur-
ing the course of the disease, especially after the second 
relapse. In addition, the involvement of more than three 
spinal segments that included cervico-thoracic segments 
(Fig 1) was present in all children. 
Disease course
All patients presented a relapsing-remitting course, 
with a median time of six months (range two to eight 
months) to the second relapset, and an average number 
of attacks of 4.16.
Brain involvement
Although the initial presentation of ON and the 
subsequent development of TM was the main form of 
the disease observed in this sample, another clinical pre-
sentations were observed, including crural parapare-
sis followed by ON or ON appearing concurrently with 
TM. Four patients exhibited abnormalities on brain MRI 
from disease onset, but only three developed symptoms 
related to brain disease during the course of the disor-
der (patients 2, 5 and 6). Headache, vomiting and vertigo 
occurred during the third clinical relapse in patient 2, 
while aphasia was documented among other findings in 
patient 5. Patient 6 exhibited seizures, somnolence and 
irritability as part of her second clinical relapse. Table 
1 shows the distribution of the lesions. Although most 
of the changes were nonspecific, these three patients 
displayed atypical lesions which included large confluent 
cerebral or diencephalon lesions, periventricular lesions 
in the temporal horns of the lateral ventricles, and juxta-
cortical and central white matter lesions (Fig 2). Patients 
5 and 6 had the most striking brain involvement with 
extensive signal abnormalities in the periventricular white 
matter and corpus callosum (Fig 2). The MRIs follow 
up displayed increased brain involvement and progres-
sive brain atrophy in two patients (patient 5 and 6). It is 
important to mention that none of the images reviewed, 
or the recorded lesions fulfilled the Barkhof criteria 
for MS17. 
Serology
NMO-IgG antibody was tested in five patients, with 
positive results in four of them (80%). At different stag-
es of the disorder, five patients underwent cerebrospinal 
fluid (CSF) analysis, two had pleocitosis (35 and 20 cells/
mm3), while other two had normal cell count. Oligoclo-
nal bands were negative in all cases, and none of the pa-
tients had serologic evidence of other autoimmune anti-
bodies or disorders.
Treatment 
All patients received high-doses of methylpredniso-
lone for the treatment of the acute attacks. One patient 
was treated with intravenous immunoglobulin for one 
acute attack (patient 2). Four patients were treated with 
prednisone and azathioprine simultaneously (patients 2, 
3, 5 and 6).Three of the patients were initially diagnosed 
as MS, and for that reason they received Interferon b1a 
until the final diagnosis was achieved (patients 1, 5 and 6). 
DISCUSSION
As an uncommon entity in pediatric ages, the clini-
cal features of NMO are still being characterized. The de-
mographic features of this sample were similar to those of 
other cohorts with adults or children, most of the cases 
were female and all children were from non-white pop-
ulations, one of them being Amerindian6,8,17,18. Recently, 
race has been considered an important demographic vari-
able for NMO in children, with a predominance of Lat-
in American and African ancestry6, and occurring also 
more frequently in non-white racial groups16,19. Race-re-
lated findings might indicate that Northern European an-
cestry is not as determinant in pediatric-onset demyelin-
ating disorders as it is in the adult NMO population8,19. 
The clinical manifestations in this small sample point 
toward a diverse initial presentation of NMO in Hispan-
ic children. The optic involvement was bilateral in all pa-
tients, leading to bilateral optic atrophy. We consider this 
an important finding, not only for being the most common 
presentation of the disease in this sample, but also be-
cause of the ON sequelae: 60% of the children were blind 
and 40% had some kind of visual impairment. It seems 
then, that ON is the most impairing feature in NMO.
Spinal cord lesions evidenced by spinal MRI had been 
reported as the single most useful diagnostic feature in 
the NMO spectrum disorder, both in adults and chil-
dren7,20. For our sample, this additional criterion was ob-
served in the entire group. However, there are patients 
with NMO who do not have the specific lesion length 
characteristic of the disorder thus stressing the support-
ive condition of this criterion.
Four of our cases exhibited the disseminated nature 
of the central white matter demyelination that extended 
beyond the optic nerves and spinal cord which is another 
supportive criteria according to the most recent classifica-
tion11. In fact, recent studies have reported a high frequen-
cy of brain MRI abnormalities in patients who fulfill crite-
ria for NMO14,15,21, including nonspecific lesions, atypical 
and thalamic or hypothalamic lesions that could be related 
to hypothalamic endocrinopathies, and also extensive ce-
rebral white matter lesions8,22. As mentioned before, three 
patients exhibited signal abnormalities in the dienceph-





Symptoms related to brain disorders, which have been 
reported in other pediatric series, were observed in our 
sample8-16. Throughout the study, one of our patients pre-
sented headache, vomiting and vertigo, another had sei-
zures while other had symptoms of expressive aphasia 
in the course of the disorder, probably related to an ex-
tensive tumefactive white matter lesion in the left hemi-
sphere. Moreover, in four patients there were an atypical 
brain MRI since the initial relapse with extensive brain 
damage on follow-up. Such evolution pattern has been 
well described in NMO literature and should prompt 
neuropediatricians to follow-up their NMO patients, with 
brain MRI, regardless of the initial presentation. 
Inclusion of the autoantibody testing in the recently 
revised diagnostic criteria for NMO led to the distinction 
of this disorder from MS and other autoimmune CNS dis-
eases. This antibody, which has 73% sensitivity and 91% 
specificity, has classified NMO as a brain blood barrier 
channelopathy with abnormal humoral immunity activa-
tion12. It was positive in 80% of the patients in our sample. 
However, 10 to 25 % of the patients clinically diagnosed 
as NMO are seronegative for NMO-IgG. An important 
finding for our sample was that all the patients who had 
positive NMO-IgG were the same who showed brain le-
sions at the MRI. Published studies report that sites of 
high brain aquaporin 4 expressions seem to correspond 
with brain MRI abnormalities in this group of patients13,23. 
According to our findings, we can conclude that de-
mographic characterization of NMO in children is similar 
to adults’, exhibiting a higher prevalence of females and 
non-white populations. The characterization of this en-
tity in children could be done by using the new 2006 cri-
teria, with an emphasis on the possibility of brain lesions 
or symptoms of brain involvement that do not meet MS 
criteria. The presence of ON and TM as required crite-
ria, in addition to the three supportive criteria in pediat-
ric samples, was also evident in this study. 
This study highlights the association of seropositiv-
ity of NMO-IgG and the presence of brain lesions in 
the NMO pediatric group. The heterogeneity of symp-
toms and neuroimaging characterization suggest that the 
term “neuromyelitis optica” should be applied to a broad-
er clinical syndrome in pediatric patients.
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